Medical Pharmacology: Chapter 36 — Antiviral Pharmacology -- Module 4

Chapter 36 — Antiviral Pharmacology — Module 4 — Hepatitis B and C Pharmacology

1. Two patients are counseled on the same day. One has chronic hepatitis B virus (HBV) infection and is told oral therapy will likely be lifelong; the other has chronic hepatitis C virus (HCV) infection and is told a 12-week course can be curative. A student asks you to reconcile these opposite messages using the underlying virology. Which single integrated explanation best accounts for both?

A) HBV is an RNA virus cleared by host nucleases, whereas HCV is a DNA virus that integrates permanently
B) Both viruses persist in the nucleus, but only HCV polymerase can be fully inhibited by available drugs
C) HCV replicates more slowly than HBV, so finite therapy outpaces HCV but never HBV
D) HBV maintains nuclear covalently closed circular DNA (cccDNA) that allows rebound after therapy, while HCV is cytoplasmic with no archived reservoir, so suppression eradicates it
E) HBV has no resistance barrier while HCV has an absolute one, which alone determines curability

ANSWER: D

Rationale:

The contrast is explained by reservoir biology integrated with replication site. HBV maintains a stable pool of cccDNA in the hepatocyte nucleus; because this transcriptional template is not eliminated by nucleos(t)ide analogues, HBV DNA rebounds when therapy stops, so suppression is indefinite. HCV replicates entirely in the cytoplasm with no integrated or nuclear reservoir, so sustained suppression removes the virus and finite therapy is curative.

Option A: Option A is incorrect: HBV is a DNA virus and HCV an RNA virus — the labels are reversed — and HCV does not integrate.
Option B: Option B is incorrect: HCV does not persist in the nucleus; the absence of a nuclear reservoir for HCV is precisely what permits cure.
Option C: Option C is incorrect: relative replication speed is not the basis of curability; reservoir persistence is.
Option E: Option E is incorrect: while sofosbuvir has a near-absolute barrier, resistance barrier alone does not explain why HBV cannot be cured — cccDNA persistence does.

2. A hepatitis C virus patient with decompensated cirrhosis (Child-Pugh C) is being evaluated. The team understands that nonstructural protein 3/4A (NS3/4A) protease inhibitors are contraindicated here, yet sofosbuvir-based therapy is acceptable. Which integrated pharmacologic reasoning best explains this difference?

A) Protease inhibitors are renally eliminated and accumulate in cirrhosis, whereas sofosbuvir is not
B) Protease inhibitors are hepatically metabolized substrates whose concentrations rise markedly in hepatic impairment, increasing toxicity, while sofosbuvir lacks this hazardous accumulation
C) Sofosbuvir is an immune modulator that is safe in liver failure, whereas protease inhibitors suppress immunity
D) Protease inhibitors require gastric acidity that decompensated patients lack, so they simply fail to absorb
E) Sofosbuvir has a lower resistance barrier that paradoxically makes it safer in advanced disease

ANSWER: B

Rationale:

The contraindication integrates metabolism with hepatic reserve. NS3/4A protease inhibitors are hepatically handled, and in decompensated cirrhosis their plasma concentrations increase dramatically, raising toxicity — which is why they are contraindicated in Child-Pugh B and C disease. Sofosbuvir does not undergo this dangerous concentration rise, so sofosbuvir/velpatasvir with or without ribavirin remains the preferred approach.

Option A: Option A is incorrect: the protease inhibitor problem in cirrhosis is hepatic accumulation from impaired metabolism, not renal accumulation.
Option C: Option C is incorrect: sofosbuvir is a polymerase chain terminator, not an immune modulator, and protease inhibitors are not contraindicated because of immunosuppression.
Option D: Option D is incorrect: the contraindication reflects toxic hepatic accumulation, not failed gastric-acid-dependent absorption.
Option E: Option E is incorrect: sofosbuvir's high resistance barrier is unrelated to its safety in hepatic impairment, and a low barrier would not confer safety.

3. A hepatitis B surface antigen (HBsAg)-positive patient with low baseline HBV deoxyribonucleic acid (DNA) and active hepatitis C virus (HCV) infection begins direct-acting antiviral (DAA) therapy without HBV-active coverage and develops a sharp rise in HBV DNA with hepatitis. Which integrated mechanism best explains why curing HCV precipitated this HBV flare?

A) DAAs directly stimulate HBV reverse transcriptase as an off-target effect
B) Clearing HCV raises gastric pH, increasing intestinal absorption of latent HBV
C) DAAs induce cytochrome P450 enzymes that activate a dormant HBV prodrug state
D) HCV cure depletes hepatocyte cccDNA stores, which rebound as HBV
E) HCV-driven interferon-stimulated gene (ISG) signaling had been suppressing HBV; eliminating HCV removes that suppression, allowing HBV reactivation

ANSWER: E

Rationale:

This integrates inter-viral immunology with treatment effect. In co-infection, HCV often dominates and drives interferon-stimulated gene signaling that suppresses HBV replication, keeping HBV DNA low. When DAAs eliminate HCV, that ISG-mediated suppression dissipates, and HBV can reactivate — occasionally causing severe hepatitis. This is why HBsAg-positive patients need concomitant HBV-active therapy during HCV treatment.

Option A: Option A is incorrect: DAAs target HCV proteins and do not directly stimulate HBV reverse transcriptase.
Option B: Option B is incorrect: HBV reactivation is an immunologic unmasking phenomenon, not a pH-driven absorption event.
Option C: Option C is incorrect: reactivation reflects loss of interferon-mediated suppression, not CYP-mediated activation of a prodrug.
Option D: Option D is incorrect: cccDNA is an HBV reservoir and is not created by HCV cure; HCV does not convert into HBV.

4. A 45-year-old patient with chronic hepatitis B and normal renal function asks why a clinician might still favor tenofovir alafenamide (TAF) over tenofovir disoproxil fumarate (TDF) even when both suppress the virus equally and resistance is not a concern. Which integrated rationale best frames the decision?

A) TAF delivers tenofovir to hepatocytes at roughly one-quarter the systemic exposure of TDF, so over the indefinite duration HBV therapy requires, its lower cumulative renal and bone toxicity becomes the deciding advantage
B) TAF achieves higher HBsAg loss rates, making the duration of therapy shorter than with TDF
C) TAF has a higher resistance barrier than TDF, which matters more the longer therapy continues
D) TAF can be stopped intermittently without viral rebound, unlike TDF
E) TAF is an immune-based therapy and therefore avoids the chain-termination toxicity of TDF

ANSWER: A

Rationale:

This integrates prodrug pharmacokinetics with the time horizon of therapy. Because HBV nucleos(t)ide therapy is generally indefinite, cumulative exposure matters. TAF's prodrug design delivers active tenofovir to hepatocytes at roughly one-quarter the systemic tenofovir exposure of TDF, reducing renal and bone toxicity that would otherwise accumulate over years — which is why it can be preferred even when efficacy and resistance are equivalent.

Option B: Option B is incorrect: TAF and TDF produce comparable virologic suppression and do not differ meaningfully in HBsAg loss, and neither shortens HBV therapy duration.
Option C: Option C is incorrect: the two share an equally high resistance barrier; TAF is not superior in this respect.
Option D: Option D is incorrect: HBV DNA rebounds when either agent is stopped because cccDNA persists; intermittent dosing is not a TAF feature.
Option E: Option E is incorrect: TAF is a nucleotide analogue chain terminator, not an immune-based therapy.

5. A trainee proposes treating hepatitis C virus with a single nonstructural protein 5A (NS5A) inhibitor first and adding sofosbuvir only if relapse occurs, reasoning that this "saves" a drug. Integrating resistance-barrier theory with combination pharmacology, why is the standard fixed-dose combination superior?

A) Sequential monotherapy is superior because it exposes the virus to one mechanism at a time
B) Combination therapy works only because it doubles the plasma concentration of each agent
C) Combining a low-barrier NS5A inhibitor with high-barrier sofosbuvir means no single mutation escapes both targets, suppressing resistance that NS5A monotherapy would readily select
D) NS5A inhibitors have an absolute resistance barrier, so monotherapy is actually adequate
E) Sofosbuvir alone is curative, so the NS5A inhibitor is pharmacologically redundant

ANSWER: C

Rationale:

This integrates the differing resistance barriers of the two classes with the logic of combination therapy. NS5A inhibitors have a relatively low genetic barrier and would readily select resistance as monotherapy, whereas sofosbuvir has a near-absolute barrier. Combining them at non-overlapping targets means a virus would need simultaneous resistance to both, which is exceedingly unlikely — so the combination suppresses resistance that sequential NS5A monotherapy would invite.

Option A: Option A is incorrect: exposing the virus to one mechanism at a time is exactly what permits stepwise resistance selection.
Option B: Option B is incorrect: the benefit is non-overlapping mechanisms, not a doubling of each drug's concentration.
Option D: Option D is incorrect: NS5A inhibitors have a low, not absolute, barrier, so monotherapy is inadequate.
Option E: Option E is incorrect: sofosbuvir is not used as curative monotherapy; the NS5A partner is essential, not redundant.

6. A patient on rosuvastatin and amlodipine is starting glecaprevir/pibrentasvir for hepatitis C virus. Integrating glecaprevir's transporter effects with statin handling, which management step is required, and why?

A) Increase the rosuvastatin dose, because glecaprevir induces statin metabolism
B) Stop amlodipine, because glecaprevir blocks its renal elimination
C) No change is needed, because glecaprevir does not affect transporters
D) Switch rosuvastatin to a higher-potency statin to overcome reduced absorption
E) Discontinue rosuvastatin, because glecaprevir inhibits organic anion transporting polypeptide (OATP) uptake transporters and raises statin concentrations, making rosuvastatin contraindicated

ANSWER: E

Rationale:

This integrates transporter pharmacology with statin disposition. Glecaprevir inhibits OATP1B1 and OATP1B3, the hepatic uptake transporters that clear several statins; inhibiting them raises statin plasma concentrations. Rosuvastatin is especially affected and is contraindicated with glecaprevir/pibrentasvir, so it should be discontinued (other statins require dose limitation).

Option A: Option A is incorrect: glecaprevir raises statin levels via transporter inhibition rather than inducing metabolism, so increasing the dose worsens toxicity risk.
Option B: Option B is incorrect: the clinically important interaction is with the statin, not amlodipine, and the mechanism is uptake-transporter inhibition, not blocked renal elimination.
Option C: Option C is incorrect: glecaprevir does affect transporters; ignoring this risks statin toxicity.
Option D: Option D is incorrect: the problem is elevated statin exposure, not reduced absorption, so switching to a higher-potency statin is exactly wrong.

7. A hepatitis C virus patient with an estimated glomerular filtration rate (eGFR) of 18 mL/min/1.73m² who is not yet on dialysis needs treatment. Integrating the elimination routes of the candidate drugs with this renal function, which regimen choice is best supported and why?

A) Sofosbuvir/velpatasvir, because sofosbuvir metabolites are cleared by the liver at low eGFR
B) Glecaprevir/pibrentasvir, because both components are biliary-excreted and avoid the renal accumulation that limits sofosbuvir below eGFR 30 mL/min/1.73m²
C) Ledipasvir/sofosbuvir plus ribavirin, because ribavirin offsets sofosbuvir accumulation
D) Sofosbuvir monotherapy, because a single renally cleared agent minimizes interaction risk
E) Sofosbuvir/velpatasvir/voxilaprevir, because adding voxilaprevir restores renal safety

ANSWER: B

Rationale:

This integrates drug elimination with renal threshold. Sofosbuvir's inactive metabolite is predominantly renally eliminated, and sofosbuvir is not recommended below an eGFR of 30 mL/min/1.73m² because of accumulation concerns. Glecaprevir and pibrentasvir are both primarily biliary-excreted, so glecaprevir/pibrentasvir avoids this problem and is preferred in severe renal impairment, including dialysis.

Option A: Option A is incorrect: sofosbuvir's metabolite is renally, not hepatically, cleared, so sofosbuvir/velpatasvir is the agent of concern at this eGFR.
Option C: Option C is incorrect: ribavirin is itself renally eliminated and causes hemolytic anemia in renal impairment, so it worsens rather than offsets the problem.
Option D: Option D is incorrect: sofosbuvir is never used as monotherapy and is renally cleared, making it doubly inappropriate here.
Option E: Option E is incorrect: adding voxilaprevir does not remove the sofosbuvir component or its renal accumulation concern.

8. A patient with hepatitis C virus and established cirrhosis achieves sustained virological response at 12 weeks (SVR12) and asks why, if he is "cured," he still needs ultrasound every six months indefinitely. Integrating what SVR12 does and does not change, which explanation is correct?

A) SVR12 is not actually durable in cirrhosis, so surveillance is really retreatment monitoring
B) Surveillance continues only to detect reinfection, not cancer
C) SVR12 eliminates hepatocellular carcinoma risk, but ultrasound is required for insurance documentation
D) SVR12 durably eradicates the virus and lowers — but does not eliminate — hepatocellular carcinoma risk in established cirrhosis, so imaging surveillance continues indefinitely
E) Surveillance is needed because cirrhosis reverses fully after SVR12, creating new screening requirements

ANSWER: D

Rationale:

This integrates the meaning of virologic cure with persistent structural liver risk. SVR12 durably eradicates HCV and reduces the risk of hepatocellular carcinoma, but in patients with established cirrhosis that risk is lowered rather than abolished, because the cirrhotic liver remains a substrate for carcinogenesis. Therefore ultrasound surveillance every six months continues indefinitely even after cure.

Option A: Option A is incorrect: SVR12 is durable; the surveillance is for cancer risk in the cirrhotic liver, not viral relapse.
Option B: Option B is incorrect: surveillance targets hepatocellular carcinoma; reinfection is monitored separately with HCV RNA testing.
Option C: Option C is incorrect: SVR12 reduces but does not eliminate cancer risk, and the surveillance is medically indicated, not merely documentary.
Option E: Option E is incorrect: cirrhosis does not reliably reverse fully after SVR12; residual structural risk is the reason surveillance persists.

9. A patient is started on entecavir for chronic hepatitis B. Months later, unrecognized HIV infection is discovered, and HIV resistance testing now shows the methionine-to-valine substitution at codon 184 (M184V). Integrating entecavir's pharmacology with HIV resistance, what is the most likely explanation?

A) Entecavir has enough incidental anti-HIV activity to apply selective pressure, and as functional monotherapy against HIV it selected the M184V resistance mutation
B) Entecavir directly mutates the HIV genome through its chain-termination mechanism
C) M184V is an HBV resistance mutation that was misreported as HIV
D) Entecavir has no anti-HIV activity, so the mutation must predate any therapy and is unrelated
E) Entecavir boosted HIV replication, which independently generated random resistance

ANSWER: A

Rationale:

This integrates the unexpected cross-activity of an HBV drug with HIV resistance selection. Although entecavir was initially thought to lack meaningful anti-HIV activity, it has enough to exert selective pressure on HIV. Given alone without a fully suppressive antiretroviral regimen, it acted as functional HIV monotherapy and selected the M184V resistance substitution — which is why HIV-positive patients receiving entecavir must also be on a suppressive antiretroviral regimen.

Option B: Option B is incorrect: the drug applies selective pressure favoring pre-existing resistant variants; it does not directly mutate the viral genome.
Option C: Option C is incorrect: M184V is a recognized HIV reverse transcriptase resistance mutation, not an HBV mutation.
Option D: Option D is incorrect: entecavir does have clinically relevant anti-HIV activity, which is precisely the source of the problem.
Option E: Option E is incorrect: resistance arose from selective pressure under functional monotherapy, not from drug-enhanced viral replication.

10. A program adopts pangenotypic hepatitis C virus regimens and proposes dropping genotype testing entirely. Integrating why pangenotypic therapy reduced the need for genotyping with the situations where genotype still carries weight, which statement is most accurate?

A) Genotype testing must always precede any modern regimen regardless of context
B) Genotype is now clinically meaningless and never affects management
C) Pangenotypic regimens make pretreatment genotyping unnecessary in most settings, but genotype still informs sequencing after treatment failure and regimen choice in resource-limited settings
D) Genotype matters only for choosing between tenofovir formulations
E) Pangenotypic regimens work by first converting all genotypes to genotype 1

ANSWER: C

Rationale:

This integrates the impact of pangenotypic potency with residual clinical relevance. Because pangenotypic regimens are active across all genotypes, pretreatment genotyping is unnecessary in most settings and treatment is simplified. However, genotype knowledge still matters when sequencing therapy after treatment failure and when selecting genotype-specific regimens in resource-limited settings where cost favors them.

Option A: Option A is incorrect: pangenotypic therapy specifically removes the need for routine pretreatment genotyping in most patients.
Option B: Option B is incorrect: genotype is not meaningless; it retains value in failure sequencing and resource-limited choices.
Option D: Option D is incorrect: genotype concerns HCV regimen selection, not the choice between HBV tenofovir formulations.
Option E: Option E is incorrect: pangenotypic regimens act across genotypes directly; they do not convert genotypes.

11. A patient on a high-dose proton pump inhibitor (PPI) for severe reflux is starting sofosbuvir/velpatasvir. A colleague suggests simply moving the PPI to bedtime, several hours apart from the antiviral. Integrating velpatasvir's absorption requirement with PPI pharmacology, why is that separation strategy inadequate?

A) Velpatasvir requires alkaline conditions, so the PPI should be increased rather than limited
B) PPIs raise velpatasvir levels, so any PPI use mandates a velpatasvir dose reduction
C) Separation works perfectly because PPIs act only at the moment they are swallowed
D) The interaction is hepatic metabolism, so absorption timing is irrelevant
E) PPIs produce a sustained rise in gastric pH that persists across the day, reducing velpatasvir absorption regardless of timing, so the PPI must be dose-limited and taken simultaneously with the antiviral

ANSWER: E

Rationale:

This integrates the pH-dependence of velpatasvir absorption with the prolonged pharmacodynamic effect of PPIs. Velpatasvir needs an acidic stomach for absorption, and PPIs raise gastric pH for an extended period across the day, not only at the moment of dosing — so simply separating the doses does not restore acidity when the antiviral is absorbed. The correct approach is to limit the PPI to an omeprazole-equivalent of 20 mg and take it simultaneously with sofosbuvir/velpatasvir.

Option A: Option A is incorrect: velpatasvir requires acidic, not alkaline, conditions, and increasing the PPI worsens the problem.
Option B: Option B is incorrect: PPIs lower, not raise, velpatasvir exposure, and the fix is PPI dose limitation plus simultaneous dosing, not velpatasvir reduction.
Option C: Option C is incorrect: PPIs produce sustained acid suppression well beyond the moment of ingestion, so timing separation fails.
Option D: Option D is incorrect: this is a pH-dependent absorption interaction, not a hepatic metabolism interaction, so absorption timing is central.

12. A patient with HIV/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection and a CD4 count of 130 cells/mm³ is mapped out for full treatment. Integrating immune-reconstitution timing with the requirement to protect against HBV throughout, which overall plan is correct?

A) Cure HCV first, then start HIV therapy, then add HBV coverage only if reactivation occurs
B) Suppress HIV and allow immune reconstitution first, treat HCV with a compatible regimen while a tenofovir-based backbone covers HBV, and continue that HBV-active backbone indefinitely after HCV cure
C) Treat all three infections with a single agent simultaneously to avoid sequencing errors
D) Treat HBV with peginterferon, defer HIV therapy, and cure HCV last
E) Cure HCV, then switch to an HBV-inactive antiretroviral regimen to reduce toxicity

ANSWER: B

Rationale:

This integrates immune reconstitution with continuous HBV protection. With advanced immunodeficiency, HIV should be suppressed and immune reconstitution allowed first, since reconstitution itself improves HCV outcomes. HCV is then treated with an antiretroviral-compatible regimen while a tenofovir-based backbone simultaneously suppresses HBV, and that HBV-active backbone must be continued indefinitely after HCV cure to prevent reactivation.

Option A: Option A is incorrect: deferring HIV therapy at a low CD4 count is unsafe, and HBV must be covered preemptively, not only after reactivation.
Option C: Option C is incorrect: no single agent treats all three viruses; coordinated multi-drug therapy is required.
Option D: Option D is incorrect: peginterferon is not the strategy here, and deferring HIV therapy in advanced immunodeficiency is hazardous.
Option E: Option E is incorrect: switching to an HBV-inactive regimen after HCV cure is the classic catastrophic error that precipitates HBV reactivation.

13. Oral nucleos(t)ide analogues suppress hepatitis B virus (HBV) more potently and conveniently than peginterferon alfa, yet peginterferon remains the agent chosen when a patient specifically wants a finite course with a chance of lasting off-treatment control. Integrating peginterferon's mechanism with its clinical endpoint, why does it retain this niche?

A) Peginterferon combines direct antiviral activity via interferon-stimulated gene induction with restoration of HBV-specific immune responses, enabling durable off-treatment outcomes such as HBeAg seroconversion that suppressive nucleos(t)ide analogues do not reliably produce
B) Peginterferon eliminates cccDNA directly, which is why it cures HBV in a finite course
C) Peginterferon has a higher resistance barrier than tenofovir, so finite therapy avoids resistance
D) Peginterferon is preferred because it is safe in decompensated cirrhosis where oral agents are not
E) Peginterferon achieves finite therapy by being a more potent chain terminator than entecavir

ANSWER: A

Rationale:

This integrates mechanism with endpoint. Peginterferon acts both directly — inducing interferon-stimulated genes that inhibit HBV replication — and immunologically, restoring HBV-specific T-cell responses. This immune-mediated action can produce durable off-treatment responses such as HBeAg seroconversion and, rarely, HBsAg loss, which suppressive nucleos(t)ide analogues do not reliably achieve. That capacity for lasting off-treatment control is why peginterferon retains its finite-therapy niche despite being less potent and less convenient.

Option B: Option B is incorrect: peginterferon does not eliminate cccDNA; its value lies in immune-mediated durable response, not reservoir eradication.
Option C: Option C is incorrect: peginterferon is immune-based and not characterized by a resistance barrier; tenofovir's barrier is already very high.
Option D: Option D is incorrect: peginterferon is contraindicated in decompensated cirrhosis, the opposite of this claim.
Option E: Option E is incorrect: peginterferon is not a chain terminator at all; that mechanism belongs to the nucleos(t)ide analogues.